Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector

Jiang, Yongping; Yu, Kangzhen; Zhang, Hongbo; Zhang, Pingjing; Li, Chenjun; Tian, Guobin; Li, Yanbing; Wang, Xijun; Ge, Jinying; Bu, Zhigao; Chen, Hualan

doi:10.1016/j.antiviral.2007.03.009

Cited by 86 publications

(62 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, poor humoral response has been previously reported with a homologous DNA-DNA prime-boost vaccination strategy (Suguitan et al, 2011). It is worth noting that in the present study, the absence of HI titers was directly related to the lowering of protective efficacy, in contrast to previous studies that showed protection in chickens despite the lack of any detectable anti-HA antibody titer (Kodihalli et al, 1997;Jiang et al, 2007).…”

Section: Discussioncontrasting

confidence: 55%

“…The sole surviving chicken from this group was able to produce significantly high HI titer post-challenge, indicating proper induction of B-cell memory. The absence of anti-HA antibodies in such DNA-vaccinated groups was not surprising because previous dose-response studies have demonstrated variability in induction of HI antibodies, which play a major role in protection against avian influenza (Jiang et al, 2007). Moreover, poor humoral response has been previously reported with a homologous DNA-DNA prime-boost vaccination strategy (Suguitan et al, 2011).…”

Section: Discussionmentioning

confidence: 97%

“…DNA vaccination, therefore, has the advantage of eliciting immune responses similar to those in natural infection without the risk of handling live infectious agents (Khan, 2013). Previous studies have explored the use and efficacy of HA-based DNA vaccination against avian influenza in chicken (Fynan et al, 1993a;Robinson et al, 1993;Jiang et al, 2007). In the present study, HA1 gene of an Egyptian HPAI H5N1 virus was successfully cloned into pcDNA3.1D TOPO mammalian expression vector and expressed in vitro to be used in prime-boost strategy with inactivated H5N2 vaccine.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Protective efficacy of a prime-boost protocol using H5-DNA plasmid as prime and inactivated H5N2 vaccine as the booster against the Egyptian avian influenza challenge virus

Hussein¹,

Ahmed²,

Aly³

et al. 2016

View full text Add to dashboard Cite

Summary. -In this study, a recombinant DNA plasmid was constructed, encoding for HA1 of a selected Egyptian H5N1 virus (isolated during the 2012 outbreaks). In the immunization and challenge experiments, SPF chickens received 1 or 2 doses of H5-DNA plasmid prime, and boosted with the inactivated H5N2 vaccine. Haemagglutination inhibition (HI) titers, protection levels, and the magnitude of virus shedding were compared to that of the chickens that received either DNA plasmid or inactivated H5N2 vaccine alone. H5N1 virus A/chicken/Egypt/128s/2012 (H5N1) highly pathogenic avian influenza (HPAI) clade 2.2.1/C was used for the challenge. Chickens immunized with 1 or 2 doses of H5-DNA vaccine failed to overcome the challenge with 0% and 10% protection, respectively. Quantitative real-time reverse transcription-PCR revealed virus shedding of 2.2 x 10 4 PCR copies/ml 3 days post challenge (dpc) in the only surviving bird from the group that received 2 doses of plasmid. However, chickens immunized with 1 or 2 doses of H5-DNA plasmid as prime and inactivated H5N2 vaccine as booster, showed 80% protection after challenge, with a viral shedding of 1.2 x 10 4 PCR copies/ml (1 dose) and 1.6 x 10 4 PCR copies/ml (2 doses) 3 dpc. The surviving birds in both groups did not shed the virus at 5 and 7 dpc. In H5N2-vaccinated chickens, protection levels were 70% with relatively high virus shedding (1.8 x 10 4 PCR copies/ml) 3 dpc. HI titers were protective to the surviving chickens. This study reports the efficacy of H5-DNA plasmid to augment reduction in viral shedding and to provide better protection when applied in a prime-boost program with the inactivated AI vaccine.Keywords: avian H5N1 influenza; inactivated H5N2 vaccine; DNA plasmid; hemagglutinin; prime-boost Email: husvirol@cu.edu.eg; phone: +201002159364. Abbreviations: AI(V) = avian influenza (virus); dpc = days post challenge; EID 50 = egg infective dose (50%); HA1 = hemagglutinin one (the part representing influenza hemagglutinin globular head); HI = hemagglutination inhibition; HPAI = highly pathogenic avian influenza; qRT-PCR = quantitative real-time reverse transcriptionpolymerase chain reaction; SPF = specific pathogen free

show abstract

Section: Discussioncontrasting

confidence: 55%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Protective efficacy of a prime-boost protocol using H5-DNA plasmid as prime and inactivated H5N2 vaccine as the booster against the Egyptian avian influenza challenge virus

Hussein¹,

Ahmed²,

Aly³

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Other elements, such as intron, polyadenylation signals and the plasmid backbone sequence, can also affect the level of expression of the antigen [1] [10] [17] [18]. Moreover, the insertion of a Kozak sequence and the use of a codon optimised gene may have marked effects on gene expression efficiency [5] [17].…”

mentioning

confidence: 99%

“…The pVAX1 vector, which contains CMV/IE enhancer/promoter and BGH polyadenylation signal, but lacks an intron in its backbone, was employed to clone HA, neuraminidase (NA) and matrix (M1) consensus sequences from circulating H5 AIV to generate recombinant constructs, which induced highly cross-reactive cellular immune responses against H5 influenza antigens in mice [21]. The vector pCAGGS, containing the chicken β-actin promoter, the CMV enhancer and a rabbit β-globin poly (A) sequence has been shown to be effective in DNA vaccines for H5 AIV [5] and influenza [22]. Although many expression vectors showed their effectiveness for DNA vaccination, the data on which of these vectors will be the most useful and practical for use with DNA vaccines is seldom available.…”

mentioning

confidence: 99%

Comparison of Five Expression Vectors for the Ha Gene in Constructing a DNA Vaccine for H6N2 Influenza Virus in Chickens

Shan¹,

Ellis²,

Edwards³

et al. 2016

AiM

View full text Add to dashboard Cite

A number of eukaryotic expression vectors have been developed for use as DNA vaccines. They showed varying abilities to initiate immune responses; however, there is little data to indicate which of these vectors will be the most useful and practical for DNA vaccines in different species. This report examines the use of five expression vectors with different promoters and Kozak sequence to express the same hemagglutinin (HA) protein of an H6N2 avian influenza virus for DNA vaccination in chickens. Although intramuscular vaccination with seven DNA constructs elicited no or limited measurable H6 HA antibody responses in Hy-Line chickens, variable reduction in virus shedding for either oropharyngeal or cloacal swabs post-virus challenge were observed. This indicated that all DNA constructs generated some levels of protective immunity against homologous virus challenge. Interestingly, lower dose (50 or 100 μg) of plasmid DNAs consistently induced better immune response than higher dose (300 or 500 μg). In the transfection experiments there appeared to be a hierarchy in the in vitro expression efficiency in the order of pCAG-optiHAk/ pCAG-HAk > pCI-HAk > VR-HA > pCI-HA > pCI-neo-HA > pVAX-HA. Since the level of in vitro expression correlates with the level of immune response in vivo, in vitro expression levels of the DNA constructs can be used as an indicator for pre-selection of plasmid vaccines prior to in vivo assessment. Moreover, our results suggested that the Kozak sequence could be used as an effective tool for DNA vaccine design.

show abstract

The protective role of maternal genetic immunization on maternal‐fetal health and welfare

Ahmed,

Jiang,

Liu

et al. 2023

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Pregnancy is a critical period associated with alterations in physiologic, biologic, and immunologic processes, which can affect maternal‐fetal health through development of several infectious diseases. At birth, neonates have an immature immune system that makes them more susceptible to severe viral infections and diseases. For this reason, different maternal nutritional and immunization interventions have been used to improve the immune and health status of the mother and her neonate through passive immunity. Here, we reviewed the protective role of maternal immunization with different types of vaccines, especially genetic vaccines, during pregnancy in maternal‐fetal health, immune response, colostrum quality, immune response, and anti‐oxidative status. For this purpose, we have used different scientific databases (PubMed and Google Scholar) and other official web pages. We customized the search period range from the year 2000 to 2023 using the key words “maternal immunization” OR “gestation period/pregnancy” OR “genetic vaccination” OR “maternal‐fetal health” OR “micronutrients” OR “neonatal immunity” “oxidative stress” OR “colostrum quality”. The evidence demonstrated that inactivated or killed vaccines produced significant immune protection in the mother and fetus. Furthermore, most recent studies have suggested that the use of genetic vaccines (mRNA and DNA) during pregnancy is efficient at triggering the immune response in mother and neonate without the risk of undesired pregnancy outcomes. However, factors such as maternal redox balance, nutritional status, and the timing of immunization play essential roles in regulating immune response inflammatory status, antioxidant capacity, and the welfare of both the pregnant mother and her newborn.

show abstract

Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector

Cited by 86 publications

References 32 publications

Protective efficacy of a prime-boost protocol using H5-DNA plasmid as prime and inactivated H5N2 vaccine as the booster against the Egyptian avian influenza challenge virus

Protective efficacy of a prime-boost protocol using H5-DNA plasmid as prime and inactivated H5N2 vaccine as the booster against the Egyptian avian influenza challenge virus

Comparison of Five Expression Vectors for the Ha Gene in Constructing a DNA Vaccine for H6N2 Influenza Virus in Chickens

The protective role of maternal genetic immunization on maternal‐fetal health and welfare

Contact Info

Product

Resources

About